CD38 and medical procedure: Molecular analyses of longitudinal kidney biopsies from a phase 2 trial testing an anti-CD38 antibody for kidney transplant rejection show temporary suppression of antibody-mediated rejection during treatment, with molecular recurrence at 52 weeks.